Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Philippines FDA/Kadcyla

Approved

STANDARD

Kadcyla

F. Hoffmann-La Roche AG🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: e1e1c44cf1557a72
Company: F. Hoffmann-La Roche AG
Type: Standard

Approval Details

Approval Id: e1e1c44cf1557a72
Drug Approval Philippines Name: Kadcyla
Product Name: Kadcyla
Registration Number: BR-953
Brand Name: Kadcyla
Generic Name: Trastuzumab Emtansine
Dosage Form: Powder For Concentrate For Solution For I.V. Infusion
Dosage Strength: 100 mg
Manufacturer: F. Hoffmann-La Roche AG
Trader: F. Hoffmann-La Roche Ltd.
Importer: Roche (Philippines) Inc.
Distributor: Roche (Philippines) Inc.
Company Detail Path: /organization/f-hoffmann-la-roche-ag
Trader Detail Path: /organization/f-hoffmann-la-roche-ltd-switzerland
Issuance Date: 06 May 2024
Expiry Date: 30 June 2029
Pharmacologic Category: Monoclonal Antibody
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

e1e1c44cf1557a72

Type

Standard

Back to Philippines FDA Approvals

Kadcyla - Philippines FDA Drug Approval Details